• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Analysts see multi-year transition to growth for Embecta

September 8, 2022 By Sean Whooley

BD Diabetes Spinoff EmbectaEmbecta (Nasdaq:EMBC), the BD diabetes business spinoff, may take a few years to move into a growth phase, analysts say.

BTIG analysts Marie Thibault and Sam Eiber wrote a report labeling Embecta as a “Neutral” option on the market. BD initially announced it would spin off its diabetes business in 2021, finally completing the move in April 2022.

The company’s first quarterly results as a spinoff inspired early confidence, beating the consensus forecast on Wall Street. However, the analysts aren’t jumping at the stock too soon.

“We expect this to be a multi-year transition from a value story to a growth play,” Thibault and Eiber wrote. They went on to point out that today’s investments in commercial programs and R&D initiatives “aren’t likely to materialize” on the company’s profits and losses out to fiscal 2024.

Embecta is developing insulin administration products, including pen needles, syringes, safety pen needles and syringes. The analysts say the company will benefit from starting out as the global market leader in this space.

Developing a new insulin delivery product

It is also developing an insulin patch pump for people with type 2 diabetes. The pump features tailored alarms and a larger reservoir to hold more insulin. Embecta aims to create an easy-to-use solution requiring minimal training for patients.

CEO Devdatt Kurdikar told Drug Delivery Business News earlier this year that currently available insulin patch pumps have been developed for type 1, but Emebecta is looking to address the differences between user needs and preferences that separate the two types of diabetes.

A closed-loop version of the company’s patch pump has breakthrough device designation, and Kurdikar said it’s been helpful to work hand-in-hand with the agency to understand regulatory requirements amidst the development and align the company’s understanding with that of the FDA.

Kurdikar said the patch pump creates an “exciting opportunity” from an M&A and partnership standpoint as well. The analysts also see it as a major growth driver for Embecta.

“In our view, the development of a novel, insulin patch pump for people with type 2 diabetes (T2D) is the most significant long-term growth opportunity given the large market size and unmet need,” the analysts said. “There are an estimated ~2M people in the U.S. with T2D on intensive insulin therapy, with pump penetration in the low-to-mid single digit range for this patient group.”

Still uncertainty for Embecta

The analysts said they like that Embecta’s core market is stable, plus the company’s cash flow generation and funding for growth opportunities are positives. However, near-term market shrinkage and less visibility on product timelines add some doubt.

Thibault and Eiber said the current product pipeline is “exciting but not without risks.” They remain eager for updates on the patch pump’s progress and timeline. However, they pointed to a previous BD patch pump under development before the company withdrew its FDA application in 2019, pointing to “high uncertainty” around the future device.

Still, routes for growth remain, the analysts said.

“We think there are multiple avenues for EMBC to drive long-term growth, including through greater penetration of its core market, expanding its emerging market presence, and by entering new markets through R&D initiatives such as the T2 patch pump,” they said. “EMBC may be able to grow by making acquisitions that could scale using the company’s globally recognized brand and footprint.”

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: BD, embecta

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS